Shareholdings update - REPLACEMENT
Replacement announcement correcting share issuance details from 31 March 2025 shareholdings update.
- Additional Consideration Shares issued to Hutano former shareholders 545,455 ordinary shares of 1p each
- Employee performance-related share options issued 4,250,000 ordinary shares (unvested)
- Options awarded to Martin Walton 3,750,000 shares
- Total Voting Rights 372,058,871 Ordinary Shares
Select text to share a quote on X · sign in to keep highlights & notes in your EDX notes
The following amendments have been made to the 'Shareholdings Update' announcement released on 31/03/2025 under RNS No 7637C.
The Company has approved the issue of the following ordinary shares and share options.
545,455 new ordinary shares of 1p each ("Additional Consideration Shares") in the Company to 13 former shareholders (including employees) of Hutano Diagnostics Ltd,
4,250,000 ordinary shares, in the form of unvested options, under the 2024-25 Company employee performance-related share option scheme,
All other details remain unchanged. The full amended text is shown below.
EDX Medical Group plc
AQSE: EDX
("EDX Medical" or the "Company")
SHAREHOLDINGS UPDATE
CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces that the Company has approved the issue of the following ordinary shares and share options.
545,455 new ordinary shares of 1p each ("Additional Consideration Shares") in the Company to 13 former shareholders (including employees) of Hutano Diagnostics Ltd, ("Hutano") a 100%-owned subsidiary of the Company since September 2023. The issue of these Additional Consideration Shares to the relevant Hutano shareholders is dependent on the achievement of certain commercial milestones, in this instance the successful passing of filing of a patent covering proprietary Point of Care testing technology.
4,250,000 ordinary shares, in the form of unvested options, under the 2024-25 Company employee performance-related share option scheme, of which 3,750,000 are awarded to Mr Martin Walton, a director and deputy chair of the Company, under a performance schedule.
On March 20, EDX Medical announced the issue of 21,428, 571 new ordinary shares as a result of an equity fundraising round. The total number of shares issued has been revised to 21,428,568.
Total Voting Rights
The above figure of 372,058,871 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The directors of EDX Medical accept responsibility for the contents of this announcement.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.